These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 7099111

  • 21. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC, Gill GM, Cummings KB.
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Estramustine phosphate therapy in poorly differentiated carcinoma of the prostate.
    Edsmyr F, Esposti PL, Andersson L.
    Scand J Urol Nephrol Suppl; 1980 Sep; 55():139-42. PubMed ID: 6938017
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Treatment of advanced oestrogen-resistant prostatic carcinoma with estramustine phosphate.
    Wong AL, McGeorge A, Abel BJ.
    Clin Oncol; 1981 Jun; 7(2):163-5. PubMed ID: 7249439
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of advanced carcinoma of the prostate with Estracyt.
    Nagel R, Kölln CP.
    Prog Clin Biol Res; 1976 Jun; 6():267-84. PubMed ID: 1023214
    [No Abstract] [Full Text] [Related]

  • 31. [Total remission of prostatic cancer following treatment with Estracyt].
    Romics I.
    Orv Hetil; 1982 Jan 31; 123(5):287-9. PubMed ID: 7063244
    [No Abstract] [Full Text] [Related]

  • 32. [Estracit in the therapy of prostatic carcinoma].
    Oresić V, Nola P, Mrsić Z, Pasini J.
    Acta Chir Iugosl; 1980 Jan 31; 27 Suppl 1():587-9. PubMed ID: 7424445
    [No Abstract] [Full Text] [Related]

  • 33. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R.
    Z Urol Nephrol; 1987 Mar 31; 80(3):139-47. PubMed ID: 3300097
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Clinical experience with Estracyt.
    Nilsson T.
    Acta Urol Belg; 1980 Jan 31; 48(1):133-7. PubMed ID: 7435349
    [No Abstract] [Full Text] [Related]

  • 40. Estracyt--clinical experiences.
    Nilsson T.
    Scand J Urol Nephrol Suppl; 1980 Jan 31; 55():135-8. PubMed ID: 6938016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.